Financial News
MGC Pharmaceuticals' focus "will not change" despite psilocybin news
April 06, 2023 at 05:14 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic compound found in certain types of mushrooms.
The company will work in partnership with other pharmaceutical companies to determine the best potential use for psilocybin.
Clements says that "the focus of MGC will not change" despite the news, adding that it is fully committed to its current pipeline of products.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
Tesla’s Semi Is Finally Here—But Will It Move the Stock? ↗
Today 12:40 EDT
Rocket Lab Bounces Off Its Lows—What's Behind the Move? ↗
Today 11:30 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
